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Natural killer T (NKT) cells are a unique subset of
lymphocytes that express NK cell markers such as
CD161 and CD94, as well as a T-cell receptor (TCR) a/b,
with a restricted repertoire, which distinguishes them
from NK cells, which lack a TCR. In contrast to
conventional T-lymphocytes, the TCR of NKT cells does
not interact with that of peptide antigens presented by
classical major histocompatibility complex-encoded
class I or II molecules. Instead, this TCR recognizes
glycolipids presented by CD1d, a non-classical antigen-
presenting molecule. The rapid response of NKT cells
to their cognate antigens is characteristic of an innate
immune response, and allows the polarizing cytokines
(IFN-g and/or IL-4) to regulate adaptive immunity. NKT
cells have been found to be critical in the immune
response against viral infections and malaria, as well as
in tumor immunity, and certain autoimmune diseases.
NKT cells have been assessed to represent the ‘‘trait
d’union’’ between innate and adaptive immunity. They
play an active role in skin diseases, such as contact
sensitivity, which have been implicated in UV-induced
immunosuppression and psoriasis. Thus, NKT-cells are
emerging as an important subset of lymphocytes, with
a protective role in host defense and a pathogenic role
in certain immune-mediated disease states.
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NKT CELL BIOLOGY
What are NKT cells?
Natural killer T cells (NKT cells) are a unique subset of
T-lymphocytes that express a T-cell receptor (TCR) a/b, with a
restricted repertoire (Godfrey et al., 2004). In mice and
humans, NKT cells use a precisely rearranged homologous
TCR variable (V)a and junctional (J)a segments. In mice, most
NKT cells express an invariant TCR a chain rearrangement
(Va14-Ja18) with a conserved CDR3 region, and they
typically co-express either Vb8.2, Vb2, or Vb7. Similar
T-cells are present in other mammalian species, including
humans. The homologous population of human invariant
NKT cells express a Va24-Ja18 rearranged TCR a chain with
a Vb11-containing b chain (Porcelli et al., 1993; Dellabona
et al., 1994). The evolutionary conservation of this T-cell
receptor specificity is striking, as mouse NKT cells recognize
human CD1d plus glycolipid antigen and vice versa (Brossay
et al., 1998). This receptor distinguishes NKT cells from NK
cells, even if they share some markers characteristic of NK
cells such as CD161 (NKR-P1), known as NK1.1 in mice
(Godfrey et al., 2004). In contrast to conventional
T-lymphocytes and Tregs, the NKT cell TCR does not interact
with peptide antigen presented by classical major histocom-
patibility complex (MHC)-encoded class I or II molecules, but
instead it recognizes glycolipids presented by CD1d, a
nonclassical antigen-presenting molecule that associates with
b2 microglobulin (Godfrey et al., 2000; Kronenberg and
Gapin, 2002).
CD1 family members are monomorphic MHC class-I-like
glycoproteins that present lipid-based antigens recognized by
T-cells, even across species. The antigen-binding cleft of the
CD1 family contains large hydrophobic pockets that are
ideally suited to binding lipid antigens; CD1 glycoproteins
can be classified primarily into two groups, which differ in
their lipid anchoring: CD1a, CD1b and CD1c (group 1 CD1
molecules), and CD1d (group 2 CD1) (Zajonc and Wilson,
2007). CD1e is an intermediate form, expressed intracellu-
larly, the role of which is currently unclear (Angenieux et al.,
2000). Although humans express all family members, only
the CD1d genes are present and expressed in mice and rats.
CD1a, b, and c are homologous to each other and are
expressed by thymocytes, dendritic cells, and activated
monocytes, (Dougan et al., 2007) whereas B cells express
only CD1c, among these three family members (Small et al.,
1987). CD1d is divergent in sequence from CD1a, b and c
(Balk et al., 1989) and its tissue distribution is more
widespread, including cells outside the lymphoid and
myeloid lineages (Canchis et al., 1993; Exley et al., 2000).
In addition CD1d is expressed in epidermal keratinocytes
(KCs) in the skin, and by several other peripheral epithelia or
stromal cells in diverse organs such as the intestine, liver,
kidney, pancreas, uterus, and conjunctiva (Sieling, 2000;
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Fishelevich et al., 2006). Some bone marrow-derived cells,
such as B cells and monocyte-derived dendritic cells, also
express CD1d (Sieling, 2000). In Table 1 Cd1d expression at a
cellular level is summarized.
CD1a, b, and c molecules, which can present self and
foreign (microbial) lipid antigens, are generally recognized by
T-cells expressing diverse ab TCRs. Some TCR gd bearing
T cells recognize CD1c, in contrast to CD1d that is restricted to
NKT cells with semi-invariant TCR. Relatively few examples of
these antigens are defined, although presentation of several
mycobacterial cell wall antigens by the three other human
CD1 molecules, CD1a, CD1b, and CD1c has been well
characterized (Gumperz and Brenner, 2001), as has presenta-
tion of several autologous antigens, including gangliosides and
some phospholipids. The compound most efficient for activat-
ing the majority of NKT cells is a synthetic glycolipid
(originally derived from a marine sponge) known as a-
galactosylceramide (aGalCer) (Hong et al., 1999; Hayakawa
et al., 2004). This compound binds effectively to CD1d, and
the complex of glycolipid plus CD1d binds the NKT cell TCR
(Sidobre et al., 2002). aGalCer is widely used as a highly
specific antigen for both human and murine NKT cells.
Although most NKT cells express NK cell markers such as
CD161, they also contain a small population of cells that are
negative for NK cell markers (Godfrey et al., 2004).
Importantly, CD1d-restricted T cells also contain T-cells that
neither express the canonical TCR a-chain nor respond to
aGalCer (Duarte et al., 2004; Terabe et al., 2005). To avoid
confusion, it has recently been recommended that NKT cells
should be defined by their reactivity to aGalCer loaded onto
CD1d multimers, instead of the expression of NK cell markers
(Godfrey et al., 2004). It is apparent, now, that the simple
classification of NKT cells as T-lymphocytes that also express
NK receptors is inadequate.
Two types of NKT cells have been described: the invariant
Va14þNKT cells (iVa14þNKT, referred to hereafter as NKT
cells), also called type I NKT cells. Within the type I NKT
cells, there are two defined subpopulations: a CD4þ single
positive and a CD4CD8 DN population; they express TCR
repertoire consisting of Va14-Ja18 (in mice) or Va24-Ja18 (in
humans).
In addition to type I NKT cells, a population of CD1d-
reactive NKT cells that express diverse non-Va14TCRs,
referred to as type II NKT cells or noninvariant, has also
been described. These cells were identified based on the fact
that NKT cell function was still detectable in mice lacking
type I NKT cells but not in mice lacking CD1d (Godfrey et al.,
2004). Although type II NKT cells are also restricted by CD1d,
they do not recognize aGalCer. It is important to note,
however, that some type II NKT cells are also autoreactive, as
they recognize the endogenous myelin-derived glycolipid
sulfatide and help protect mice against the development of
experimental autoimmune encephalitis (Jahng et al., 2004).
There is yet another population of cells, classified as NKT-
like cells (Godfrey et al., 2004). This subset exhibits for
similarities in surface markers (Ly49 in mice and CD161 in
humans) but with a diverse repertoire expression, restricted to
classical MHC class I and II molecules but not the CD1d
molecule. Some authors consider this population as Type III
or CD1d-independent NKT cells (Meyer et al., 2007). Based
on the recommendations of Godfrey et al. (2004) we do not
consider this population as part of NKT cells.
During development in the murine thymus, rare CD4þ
CD8þ (DP) cortical thymocytes that successfully rearrange
the semi-invariant TCR are directed to the Va14 NKT cell
lineage by interactions with CD1d-associated endogenous
glycolipids expressed by other DP thymocytes. As they
mature, Va14 NKT lineage cells upregulate activation
markers such as CD44 and subsequently express NK-related
molecules such as NK1.1 and members of the Ly-49
inhibitory receptor family (MacDonald and Mycko, 2007).
The distribution of NKT cells and NK cells is different; NKT
cells are found everywhere that conventional T-cells are found.
In mice, NKT cells represent approximately 30% of the total
lymphocytes in the liver (50% of abTCRþ T cells), 20% of the
ab T-cells in the bone marrow, and 3% of the abT cells in the
spleen, but are rare in the lymph node (Godfrey et al., 2000;
Emoto and Kaufmann, 2003; Berzins et al., 2004). In humans,
only 0.2% of peripheral blood T-cells are NKT cells. They are
also present in the human liver but their numbers are lower
than in the liver of mice (Prussin and Foster, 1997; Norris et al.,
1999; Benlagha et al., 2000). NKT cells predominate in the
liver, whereas conventional T cells prevail in blood and lymph
node. In contrast, the order for NK cell frequency is
lung4liver4peripheral blood mononuclear cells4spleen4
bone marrow4lymph node4thymus, where NK cells are
almost undetectable (Gregoire et al., 2007).
Ligands
As aGalCer, was discovered as a potent ligand for NKT cells
(Kawano et al., 1997), a synthetic aGalCer has widely been
used for the study of NKT cells as a surrogate ligand. It is now
established that two lipid chains of aGalCer are inserted to
hydrophobic grooves of the CD1d glycoprotein expressed by
APCs (McCarthy et al., 2007), whereas the a-linked sugar
moiety is accessible and recognized by the TCR of NKT cells.
Recently, the crystal structure of the invariant TCR and CD1d
loaded with aGalCer has shown a very unique orientation of
TCR towards CD1d (Borg et al., 2007), which allows a
selective involvement of the invariant a-chain for recognition
of the a-linked sugar. Comparison of aGalCer with its
structurally altered analog has provided important insights
Table 1. CD1d expression at cellular level
Dendritic cells
Thymocytes
B cells
Monocytes
Macrophages
Epithelial cells (for example, skin, intestine)
Stromal cells (Schwann cells)
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into how NKT cells may differentially respond to glyco-
sphingolipids with lipid tail variants (Brutkiewicz, 2006;
Miyake and Yamamura, 2007). In Table 2 CD1d ligands
(synthetic, bacterial, and endogenous) are summarized.
An aGalCer analog called OCH (Miyamoto et al., 2001;
Oki et al., 2004, 2005), with a shorter sphingosine,
selectively stimulates IL-4 production from NKT cells,
whereas aGalCer stimulation induces both IL-4 and IFN-g.
Accordingly, OCH stimulation of NKT cells favors a Th2 bias
of immune responses in vivo, as compared to aGalCer
stimulation. a-linked sugars, such as aGalCer are not
recognized as a product of mammalian cells, whereas most
mammalian glycolipids have b-linked carbohydrates
attached to the lipid backbone, implying that aGalCer is
not a physiological ligand for NKT cells. Currently, it is well
recognized that NKT cells can be activated during infectious
diseases (Tupin et al., 2007). Interestingly, it has been
reported that aGalCer-like glycosphingolipids are rather
ubiquitously found in the environment, indicating that
aGalCer may be actually derived from bacteria residing with
the marine sponge. Other analogs of aGalCer have been
shown to have various effects on NKT cell activation in vitro,
as well as antimicrobial and antitumor activity in vivo. For
example, modifying the acyl chain of the aGalCer molecule
KRN7000 to create a diunsaturated 20 carbon chain results in
IL-4 production with a reduction in IFNg secretion (Yu et al.,
2005). In contrast to the effects of acyl chain modification on
aGalCer activity, Schmieg et al. (2003, 2005) used a different
approach. In their studies, they used a C-glycosidic form of
aGalCer in analyses of the adjuvant properties of aGalCer.
It was found that the C-glycoside (a-C-GalCer) acts as a natural
killer T-cell ligand in vivo, and stimulates an enhanced
Th1-type response in mice. In two disease models requiring
Th1-type responses for control, malaria, and melanoma
metastases, a-C-GalCer exhibited a 1,000-fold more potent
antimalaria activity and a 100-fold more potent antimeta-
static activity than aGalCer. Moreover, a-C-GalCer consis-
tently stimulated prolonged production of the Th1 cytokines
IFNg and IL-12, and decreased production of the Th2
cytokine IL-4 compared with aGalCer (Gonzalez-Aseguino-
laza et al., 2000, 2002; Yang et al., 2004).
Ortaldo et al. (2004), as well as Parekh et al. (2004), have
found that a 12 carbon acyl chain form of galactosylceramide
(bGalCer (C12)) can stimulate NKT cells in a CD1d-
dependent manner. The administration of the bGalCer
(C12) in vivo caused the apparent loss of NKT cells as found
with aGalCer, but without cytokine expression or activation
of NK cells. Tetramers loaded with bGalCer (C12) could stain
NKT cells, although lower numbers were detected as
compared with when aGalCer-loaded tetramers are used
(Crowe et al., 2003; Wilson et al., 2003; Harada et al., 2004).
However, some contamination with minute amounts of
aGalCer cannot be completely ruled out in either of the
bGalCer preparations. Thus, bGalCer may have some similar
yet distinctly different actions on NKT cells.
In 2005 three groups independently found that a
predominant glycosphingolipid from the LPS-free Sphingo-
monas (S. capsulata, S. paucimobilis, and S. wittichii) and
Ehrlichia muris bacteria could stimulate human and/or
murine NKT cells in a CD1d-dependent manner (Mattner
et al., 2005; Sriram et al., 2005; Kinjo et al., 2005, 2006; Wu
et al., 2005). The main glycosphingolipid identified was
aglucuronosylceramide (GSL-1); also agalacturonosylcera-
mide (GS-10) was found able to activate NKT cells. There was
a difference in identifying NKT cells with CD1d tetramers or
dimers loaded with GSL-1 with respect to the ones loaded
with aGalCer. Approximately one-half of those NKT cells that
are aGalCer/CD1d tetramer positive are GSL-1/CD1d dimer
(or tetramer) positive. Two other sources of microbial
products have been shown to be able to activate NKT cells.
The Schaible group reported that Phosphatidylinositol man-
noside (PIM) could stimulate both human and murine NKT
cells (Fischer et al., 2004). In addition, PIM-loaded CD1d
tetramers could stain both human (PBL) and mouse (liver)
NKT cells, although the latter detected a substantially smaller
population than CD1d tetramers loaded with aGalCer.
Despite this interesting observation clearly identifying PIM
as a CD1d ligand, how PIM actually participates in the
immune response against mycobacteria is not yet clear.
Search for an endogenous ligand of NKT cells has led to
the identification of lysosomal glycosphingolipid isoglobo-
trihexosylceramide (iGb3), a b-linked sugar capable of
stimulating NKT cells as a potential endogenous ligand for
mouse and human NKT cells (Zhou et al., 2004; Mattner
et al., 2005). With regard to the role of iGb3 in adaptive
immune responses, Mattner et al. (2005) reported that Gram-
negative, LPS positive Salmonella typhimurium activates NKT
cells through the recognition of iGb3, presented by LPS-
activated dendritic cells.
However, very recent works have cast a doubt on the
meaning of the iGb3 discovery (Porubsky et al., 2007; Speak
et al., 2007). The study by Zhou et al. (2004) indicated that
iGb3 presented by CD1d-expressing CD4þCD8þ thymo-
cytes should be involved in the thymic positive selection of
Table 2. NKT cell ligands presented by CD1d
Synthetic compounds aGalactosylceramide (aGalCer)
OCH (analog of aGalCer)
C20:2 analog of KRN7000
C-glycoside (analog\ of a-C-GalCer)
bGalactosylceramide (C12) (bGalCer (C12))
Bacterial recognition a-glucuronosylceramide (GSL-1)
a-galacturonosylceramide (GS-1‘)
Phosphatidylinositol mannoside (PIM)
Endogenous recognition Isoglobotrihexosylceramide (iGb3)
Disialoganglioside (GD3)
Phosphatidylinositol (PI)
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NKT cells. Porubsky et al. (2007) has then generated iGb3
synthetase-deficient mice and examined if NKT cells are
really missing in the mice lacking the expression of iGb3.
They found that the number and function of NKT cells were
as normal as those seen in wild-type mice. Using highly
sensitive HPLC assay, Speak et al., (2007) sought for the
presence of iGb3 in various mouse and human tissues. The
only tissue containing iGb3 was the dorsal root ganglion of
mice. No iGb3 was detected in any human tissue. These new
findings do not support the idea that iGb3 is central in the
selection of NKT cells and re-opened the search for
endogenous ligands for NKT cells.
Two more natural lipid components of the cell membrane,
the disialoganglioside (GD3) and Phosphatidylinositol, have
been shown to be CD1d presented Ags capable of stimulating
(at least some) NKT cells (Brutkiewicz, 2006).
Functional subsets of NKT cells
In response to antigen stimulation CD4þ T-cells differentiate
into T helper, Th1, or Th2 cells. Th1 cells produce the
signature cytokine interferon IFNg, whereas Th2 cells
produce interleukin IL-4, IL-5, IL-13, and IL-10. Similarly,
effector CD8þ T cells can be classified as Tc1 or Tc2 cells,
which produce type 1 or type 2 cytokines, respectively
(Woodland and Dutton, 2003). The Th1/Th2 paradigm has
recently been re-evaluated to include a third population of
T helper cells, producing IL-17 and designated Th17; these
cells exhibit a cytokine profile distinct from Th1 and Th2
cells, producing cytokines, such as IL-17 and IL-22, and
express a characteristic transcription factor retinoic acid
receptor-related orphan receptor g t. From this perspective,
the cytokine profiles of T-lymphocytes are thought to reflect
their functional activities. In Figure 1 a model of the
differentiation of CD4þCD8þ T-cells and activation of
NKT cells is depicted.
NKT cells are different from functionally differentiated
conventional a/b TCR bearing T-cells in that they are
autoreactive (that is, they can recognize self-glycolipids) and
produce both Th1 and Th2 cytokines upon stimulation with
their ligands (Taniguchi et al., 2003). NKT cells have been
shown to mediate both protective and regulatory immune
functions. These include tumor rejection, protection against
infectious microbes, maintenance of transplant tolerance, and
inhibition of autoimmune disease development (Taniguchi
et al., 2003). However, it remains unclear whether distinct
subsets or subtypes of CD1d-reactive NKT cells mediate
different functions. Two new studies, suggest that a distinct
subset of NKT cell mediates tumor rejection (Crowe et al.,
2005), and that type II NKT cells suppress antitumor
immunosurveillance (Terabe et al., 2005). These new studies
might help explain the seemingly contradictory functions that
have been ascribed to CD1d-reactive NKT cells. They also raise
new questions about how subsets of NKT cells acquire distinct
functional capabilities (Seino and Taniguchi, 2005).
When activated, NKT cells respond with vigorous cytokine
production within 1–2 hours of TCR ligation (Godfrey et al.,
2000; Kronenberg and Gapin, 2002). These cells release
Th1-type cytokines including IFNg and TNFa, as well as Th2-
type cytokines including IL-4 and IL-13 (Smyth and Godfrey,
2000; Wilson and Delovitch, 2003), and at least in mice, they
seem to store or pre-form some mRNA for these cytokines
even before activation with exogenous antigens (Matsuda
CD8+
CD4+
CD4+CD8+
Th1 Th2
Th17
Treg
Self tolerance
Immunesuppression
Cell-mediated immunity Humoral immunity
Allergic and parasitic responseDelayed type hypersensitivity
Pro-inflammatory response
Autoimmune disease
Bacterial , fungal protection
Antitumor immunity
Autoimmunity
Antimicrobial immunity
Th1 cytokine secretion
Th2 cytokine secretion
NKT
TCRαβ CD1d APC
Trial, FasL, Prf/Gr
Cytotoxicity
Tolerance
Figure 1. Differentiation of CD4þCD8þ T cells and activation of NKT cells. CD4þCD8þ T cells can differentiate in CD4þ , CD8þ , and NKT cells
(that can be double negative for CD4/CD8 or may be single positive for CD4 or CD8). CD4þ T cells differentiate in Th1, Th2, Th17, and Treg. Each type of these
cells is required for a specific immune response. NKT cells are stimulated by APC through CD1d–TCRab interaction and rapidly produce Th1 or Th2 cytokines.
They also have cytotoxicity activity through TRAIL, FasL, and prf/Gr.
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et al., 2003; Stetson et al., 2003). Moreover, individual NKT
cells are able to make both Th1- and Th2-type cytokines
simultaneously following stimulation in vivo (Matsuda et al.,
2000, 2003; Crowe et al., 2003). Despite this Th0-like
cytokine pattern, NKT cells can ‘‘go both ways,’’ as their
activation in some cases can polarize the immune response
in a Th1 direction, whereas in other cases a Th2 response is
generated (Godfrey and Kronenberg, 2004). In humans,
during early phase of activation, NKT cells produce both
Th1 and Th2 cytokines; during later phases of activation, they
predominantly produce proinflammatory cytokines such as
IFNg and TNFa (Gumperz et al., 2002; Lee et al., 2002a, b).
The mechanisms that determine the cytokine polarity of the
NKT cell response, and the influence of the NKT cell’s
response on the systemic immune system, are not well
understood, and indeed, this problem represents a key
challenge in the field of NKT cell research.
Two major subsets of NKT cells with distinct effector
functions have been identified. Lee et al. (2002a, b) hypothe-
sized that NKT cells could promote Th2 responses in some
conditions and Th1 in others for the presence of different
characteristics. They reported that CD4þ and DN NKT cell
subsets represent functionally distinct lineages with marked
differences in their profile of cytokine secretion and pattern of
expression of chemokine receptors, integrins, and NK
receptors. CD4þ NKT cells were the exclusive producers
of IL-4 and IL-13 upon primary stimulation, whereas DN NKT
cells had a strict Th1 profile and prominently expressed
several NK lineage receptors. Gumperz et al. (2002) also
reported different characteristics for two distinguished subsets
of NKT cells. DN NKT cells selectively produced Th1
cytokines as IFNg, TNFa and expressed NKG2D, whereas
CD4þ NKT cells potently produced both Th1 and Th2
cytokines. In an attempt to better understand the contribution
of NKT-DC crosstalk governing the Th1/2 balance, Liu et al.
(2008) demonstrated that CD4þ and DN differentially
regulate the DC function by reciprocal NKT–DC interactions,
thereby influencing the subsequent Th response. DC stimu-
lated by the CD4þ subset preferentially induced Th1
responses, whereas the DC reacted with the DN subset
induced a shift toward Th2 responses.
Although earlier studies have tended to focus on the ability
of NKT cells to downmodulate inflammatory responses, more
recent works have shown that they could promote joint
inflammation in models of arthritis (Chiba et al., 2005; Kim
et al., 2005; Ohnishi et al., 2005) or mediate airway
inflammation in bronchial asthma (Akbari et al., 2003a, b;
Lisbonne et al., 2003). The divergent effects of NKT cells in
inflammatory pathologies are thought to reflect a broad
spectrum of their functions in vivo. In fact, NKT cells
explosively produce a number of pro- and anti-inflammatory
cytokines after nonphysiological stimulation with aGalCer or
anti-CD3 mAb (Chen and Paul, 1997), although stimulation
with alternative ligands such as aGalCer analogs may lead to
selective Th1 (Schmieg et al., 2003) or Th2 cytokine production
(Miyamoto et al., 2001; Miyake and Yamamura, 2005). NKT
cells usually exhibit only a marginal response in response to
endogenous ligand bound with CD1d. However, when
cytokines are added exogenously, the cells that recognize the
endogenous ligand will produce a large amount of selected
cytokines. For example, IL-12 induces production of IFNg (Brigl
et al., 2003), whereas IL-2 provokes IL-5 and IL-13 (Sakuishi
et al., 2007). Beaudoin et al. (2002) have recently shown that
without applying any exogenous glycolipids NKT cells could
prevent the onset of diabetes in an in-vivo model, by inducing
an anergic state of the pathogenic islet-specific T cells. In
contrast to other related works, this suppression did not require
Th2 cytokines but was dependent upon direct cell–cell contact.
Although NKT cells can also exhibit cytotoxic activity similar to
CD8þ T cells, it is still unclear whether all NKT cells have this
capability (Kawano et al., 1998). At least one study in humans
demonstrated that the NKT cell pool can be divided into
cytotoxic and noncytotoxic subsets, although all NKT cell
subsets examined thus far constitutively express FasL and have
the potential for cytotoxic activity through Fas (Ho et al., 2004).
Even if human NKT cell subsets with distinct effector
functions have been identified, it is unclear whether the
effector functions of these subsets are imprinted during
development or can be selectively reprogrammed in the
periphery. Eger et al. (2006) demonstrated that NKT cells
from neonates are phenotypically and functionally distinct
from adult NKT cell subsets. In comparison to adult CD4þ
NKT cells, neonatal CD4þ NKT cells exhibit a higher
expression of the differentiation markers CCR7 and CD62L,
a lower expression of the NK cell markers CD161 and CD94,
and are more amenable to effector function reprogramming.
They also found wide heterogeneity within the adult CD4þ
NKT cell subset for expression of memory markers, suggest-
ing that the pool of CD4þ NKT cells in adult peripheral
blood represents a more heterogeneous mixture of cells with
respect to their phenotype and stage of maturation. They have
hypothesized that adult NKT cells are not recent thymic
emigrants, but have undergone some form of peripheral
maturation (Eger et al., 2006).
Antigen presentation and activation of NKT cells by
non-professional APCs
Stimulating NKT cells with aGalCer presented by profes-
sional APCs leads to production of both pro- and anti-
inflammatory cytokines. However, when non-professional
APCs such as Schwann cells (Im et al., 2006) are used,
aGalCer could induce a preferential production of Th2
cytokines from NKT cells.
Gober et al. (2008) studied antigen presentation by CD1d-
bearing KCs as well as CD1d bone marrow-derived cells.
NKT cells incubated with KCs and aGalCer did not secrete
either IFNg or IL-4 as measured by a sensitive ELISA.
In contrast, THP-1, a monocyte-derived cell line, triggered
robust IFNg secretion as well as significant IL-4 secretion.
To confirm the ELISA data, in parallel, they extracted total
cellular RNA from NKT cells and assayed IFNg and IL-4 gene
expression using real-time PCR. The PCR data confirmed that
NKT cells were triggered to activate IFNg and IL-4 gene
expression in the presence of CD1dþ monocyte cell line and
aGalCer, but not by CD1d-bearing KCs. Bonish et al. (2000)
studied the relative induction of IFNg and IL-4 production of
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three different NKT cell clones combined with either
untreated or IFNg pretreated and extensively washed KCs in
the presence of the lipid 12-O-tetradecanoyl phorbol-13-
acetate. They reported that when untreated KCs were
combined with these NK-T cell clones, virtually no IFNg
was produced, but when KCs were pretreated with IFNg, the
NK-T cell clones were stimulated to secrete IFNg. In contrast,
the production of IL-4 was relatively low and was not
consistently enhanced by combining any of the NK-T cell
clones with either untreated or IFNg pretreated KCs. They
therefore postulate that a positive feedback loop could be
established in the skin due to the presence of NK-T cells
being activated to produce IFNg upon contact with CD1d-
positive KCs, leading to further CD1d expression and
subsequent NKT cell release of more IFNg.
ROLE IN PATHOGENIC PROCESSES
Autoimmunity
The rapid response of NKT cells, which is indicative of an
innate immune response, rather than an adaptive immune
response, may allow NKT cells to regulate adaptive
immunity, such as providing protection against viral and
bacterial infection, as well as regulate autoimmune diseases,
allergic, and antitumor responses (van der Vliet et al., 2004;
Mercer et al., 2005). Thus, NKT cells have been found to be
critical in the immune response against a number of
infections including viral infections and malaria, as well as
in tumor immunity, and certain autoimmune diseases,
including diabetes, atherosclerosis, lupus, and allergic
asthma (see Table 3). It has been reported that NKT cells
can exert immuno-regulatory functions in models such as
autoimmune diseases or transplantation. The molecular
mechanisms behind these regulatory functions are not yet
fully understood, but the potent cytokine production by NKT
cells seems to be important. Recent data indicated that NKT
cells also contribute to generating regulatory dendritic cells
(DCs). It has been postulated that the immune-regulatory
functions of NKT cells are, at least in part, linked to the
generation of regulatory DCs (Wilson and Delovitch, 2003).
Naumov et al. (2001) have reported that treatment of NOD
mice with repeated injection by aGalCer induced an
accumulation of CD8a-DCs in pancreatic lymph nodes,
and inhibited disease development. These results suggest
that the interaction between NKT cells and DCs is operated
in the regulatory responses mediated by NKT cells. As
many autoimmune diseases are characterized by polarized
T-helper cell responses that can be affected by NKT cells, a
role for NKT cells in the regulation of autoimmune diseases
has been proposed. A selective reduction in NKT cell
numbers has been shown in human patients with various
autoimmune diseases, such as systemic sclerosis, systemic
lupus erythematosus, rheumatoid arthritis (RA), type 1
diabetes, and multiple sclerosis (MS) (Seino and Taniguchi,
2004).
Type I diabetes. Studies of type 1 diabetes have provided the
most evidence that NKT cells are involved in autoimmune
regulation (Linsen et al., 2005a, b). A defect in the number and
function of NKT cells in NODmice has been reported. This type
of diabetes could be ameliorated by enrichment of NKT cell
numbers through adoptive transfer or transgenic overexpression
of the invariant TCR (Hammond et al., 1998; Lehuen et al.,
1998). CD1d-deficient mice developed diabetes earlier and
experienced a greater disease penetrance and more severe
disease (Shi et al., 2001; Wang et al., 2001). In concordance,
upregulation of CD1d expression restored the immunoregula-
tory function of NKT cells and prevented autoimmune diabetes
(Falcone et al., 2004). Protection conferred by NKT cells was
associated with a Th2 shift within the pancreatic islets, and IL-4
has been implicated as a key mediator of immunoregulation
(Hammond et al., 1998; Laloux et al., 2001).
Experimental autoimmune encephalomyelitis and multiple
sclerosis. Transgenic overexpression of the invariant NKT
TCR in NOD mice protected them from experimental
autoimmune encephalomyelitis, considered as an instructive
model for human MS. This was associated with a striking
inhibition of antigen-specific IFNg production, but was
independent of IL-4 (Mars et al., 2002). In addition, studies
using aGalCer-induced NKT cell stimulation confirmed the
capacity of NKT cells to modulate the disease by inducing
Th2 cytokine profiles (Pal et al., 2001; Singh et al., 2001).
However, others reported that the protective effect was
associated with an enhanced IFNg production by liver-
confined NKT cells (Furlan et al., 2003).
MS is a chronic inflammatory disease of the central
nervous system in humans. It is a Th1-mediated autoimmune
disease that is directed at myelin antigens in the central
nervous system (Hellings et al., 2002). A decrease in Va24
mRNA in the peripheral blood of patients suffering from MS
has been demonstrated (Illes et al., 2000). In addition, the
IL-4 secretion of DN NKT cells was reduced (Gausling et al.,
2001). However, CD4þ NKT cell lines obtained from
Table 3. NKT cells in disease states
Autoimmunity Diabetes
Multiple sclerosis
Rheumatoid arthritis
Systemic lupus erythematosus
Inflammatory bowel disease
Transplantation Skin, cornea, pancreatic islet cells, liver, heart
Atherosclerosis Aorta
Allergy Allergic asthma
Allergic conjunctivitis
Infection Bacteria (for example, M. tuberculosis)
Parasites (for example, leishmania)
Yeasts (for example, C. neoformans)
Viruses (for example, cytomegalovirus)
Tumor Solid tumors (for example, lung cancer)
Myelodysplastic tumors (for example,
multiple myeloma)
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patients in remission showed a strong Th2 bias compared
with patients in relapse (Araki et al., 2003). These results
support an immunoregulatory function of NKT cells in MS
(Linsen et al., 2005a, b).
Rheumatoid arthritis. NKT cells are now reported to be
reduced in a whole range of diseases that are characterized
by autoreactive tissue damage, including RA (van der Vliet
et al., 2001). In addition, the invariant TCR transcripts were
decreased in the rheumatoid synovium (Maeda et al., 1999).
It was reported that NKT cells in RA patients showed a Th1
bias in blood and did not expand upon stimulation with
aGalCer in some patients (Kojo et al., 2001; Linsen et al.,
2005a, b). Remarkably, NKT cells in synovial fluid of all
patients responded to stimulation and displayed a Th0
cytokine profile (Linsen et al., 2005a, b). Furthermore, the
expression levels of soluble CD1d were lower in RA patients
(Kojo et al., 2003).
Lupus. Lupus-prone mice as well as patients suffering from
systemic lupus erythematosus have reduced a number of NKT
cells, which suggests a protective effect of these cells against
lupus development (Mieza et al., 1996; van der Vliet et al.,
2001). However, a possible pathogenic role of NKT cells has
been supported by experiments demonstrating that adminis-
tration of aGalCer exacerbated the disease (Zeng et al., 2003).
Transfer of activated NKT cells induced an autoimmune-like
inflammation in young lupus-prone mice (Morshed et al.,
2002) and treatment with an anti-CD1d blocking antibody
resulted in disease amelioration (Zeng et al., 2003). Yang et al.
(2003) reported that NKT cells may play a regulatory role in
the development of lupus dermatitis. As humans with lupus
and other systemic autoimmune diseases have reduced
numbers of NKT cells and lupus disease activity appears to
inversely correlate with circulating NKT cell numbers (Oishi
et al., 2001), they hypothesized that therapies aimed at the
in vivo activation of NKT cells might help to control dermatitis.
In addition, their finding that NKT cells are capable of
expansion after repeated in vivo activation may have
implications for designing NKT cell-based therapies for
chronic immunological diseases (Yang et al., 2003).
Inflammatory bowel disease and ulcerative colitis. Although
many components of the innate and adaptive immune system
contribute to intestinal immune responses, NKT cells, through
their rapid production of cytokines, play a pivotal role in
modulation of intestinal immunity. NKT cells reside in the
intestinal epithelium and the lamina propria in mice and
humans (0.5–2% of cells in these compartments) where they
modulate the host response to microbes and likely play a role
in peripheral tolerance (Zeissig et al., 2007). Studies on mouse
models of inflammatory bowel disease clearly demonstrate a
pivotal role of NKT cells in the pathogenesis of colitis. In
contrast to mice, noninvariant NKT cells seem to contribute to
the intestinal inflammation in human ulcerative colitis, whereas
NKT cells seem to be dispensable for the inflammatory process.
These studies indicate a previously unrecognized role of
noninvariant NKT cells in the intestine (Zeissig et al., 2007).
Allergy
The prevalence of allergic diseases have increased dramati-
cally worldwide over the past two decades, particularly in
industrialized countries (Mannino et al., 1998; Umetsu et al.,
2002). The environment in industrialized cultures has
changed over recent years, in ways that appear to directly
exaggerate the effects on the pathogenesis of allergic
disorders (McIntire et al., 2003).
Allergic asthma. Allergic asthma is a multifactorial respira-
tory disease involving both genetic and environmental factors
which, in combination, lead to the development of a strongly
polarized Th2 immune response towards innocuous antigens,
characterized by IgE production and tissue inflammation
including eosinophilia (Maddox and Schwartz, 2002; Cohn
et al., 2004). In airways, inflammation is accompanied by
tissue remodeling (fibrosis) and mucus hypersecretion leading
to airway hyper-reactivity (AHR). CD4þ lymphocytes
provide the necessary help to B cells for IgE production,
whereas some CD4þ subpopulations are endowed with a
regulatory role (Akbari et al., 2003a, b). The number of type 2
helper CD4þ T cells is increased in the airways of persons
with asthma. Whether the majority of these cells are class II
MHC-restricted cells or are among CD1d-restricted NKT cells
is a matter of controversy.
Vijayanand et al. (2007) reported that fewer than 2% of the
T cells obtained from all subjects on airway biopsy,
bronchoalveolar lavage, and sputum induction were invar-
iant NKT cells, with no significant differences among subjects
with asthma, subjects with chronic obstructive pulmonary
disease, and controls. No expression of messenger RNA for
the invariant NKT-cell receptor domains Va24 and Vb11 was
detected in bronchoalveolar-lavage cells from subjects with
asthma. Akbari et al. (2003a, b) reported, on the other hand,
that NKT cells are present in the lungs of asthmatic
individuals and produce high levels of IL-4 and IL-13, which
appear to regulate the development of AHR in mice. Meyer
et al. (2006) showed that activation of pulmonary NKT cells is
sufficient for the development of AHR, a cardinal feature of
asthma, in the absence of conventional CD4þ T cells and
adaptive immunity. They demonstrated that the specific and
direct activation of NKT cells by glycolipid antigens results in
the rapid induction of AHR, airway inflammation, and IgE
production, which typifies the Th2-driven response normally
associated with allergen administration. The induction of
AHR with direct NKT cell activation was independent of
eosinophils and B cells and did not occur in NKT cell-
deficient Ja18/ or CD1d/ mice.
Allergic conjunctivitis. AC is mediated by both genetic and
environmental factors, both of which lead to the polarized
Th2 immune responses that are believed to induce eosinophil
infiltration (Kumagai et al., 2006).
Fukushima et al. (2006) found that the activation of NKT
cells by intraperitoneal injection of aGalCer at the time of
sensitization augmented experimental immune-mediated
blepharoconjunctivitis (EC), whereas treatment just before
the challenge suppressed EC. The observations were in good
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agreement with previous reports of the effects of aGalCer on
experimental airway inflammation. However, they found that
topical administration of aGalCer in eye drops just prior to
challenge did not suppress EC. In contrast, it has been shown
that intranasal administration of aGalCer inhibited airway
inflammation (Hachem et al., 2005). Further work is needed
to document the functionality of NKT cells in the eye and
particularly in AC.
Transplantation
The regulatory activity of NKT cells seems to be implicated in
the induction or maintenance of immune tolerance. Although
there is evidence to suggest a role for NKT cells in the immune
response to a transplant, it remains unclear whether or not they
can recognize alloantigens directly as it has been shown that
CD1d, is not polymorphic (Balk et al., 1989). NKT cells may be
activated during transplantation by the milieu of cytokines
generated by nonspecific inflammation (Jukes et al., 2007). Oh
et al. (2005) reported that, in CD1d/ mice transplanted with
sex-mismatched skin grafts, rejection occurred in an acceler-
ated fashion compared to mice with an intact population of
NKT cells. Furthermore, activation of NKT cells with aGalcer
significantly increased graft survival in wild-type mice. In
addition, there are also a number of reports that suggest that
NKT cells may facilitate the induction of tolerance to allografts.
Sonoda et al. (2002) reported that NKT cells were essential for
allogenic corneal graft survival. Moreover, the presence of
allospecific T regulatory cells correlated well with the
acceptance of allogenic corneal grafts, and the adoptive
transfer of these cells to Ja281/ mice led to an improved
survival rate. The authors concluded that NKT cells are
required for the induction of allospecific T regulatory cells
and are thus essential for the survival of corneal allografts.
Atherosclerosis
NKT cells have also been shown to play a role in
atherosclerosis (Mercer et al., 2005). The size of athero-
sclerotic lesions in mice genetically determined to develop
atherosclerosis or fed high fat diets is enhanced by the
administration of aGalCer, dependent on CD1d or Ja18
expression (Nakai et al., 2004; Tupin et al., 2004). This is
most likely due to the enhanced expression of proinflamma-
tory cytokines by NKT cells, leading to an enhanced
activation of macrophages, B and T cells that are attracted
to the aorta (Tupin et al., 2004).
Infectious diseases
Recent findings have shown that NKT cells provide an innate-
type immune response to certain microorganisms, either
through recognition of foreign glycolipids by their invariant
antigen receptor, or by an indirect recognition mechanism in
which the invariant receptor recognizes self-antigens in the
presence of inflammatory cytokines. Overall, the data suggest
that the recognition of microbes has been a driving force in the
evolutionary selection of this T-cell subset (Kinjo and Kronen-
berg, 2005). NKT cells can clearly play a role in immunity to
bacteria, parasites, yeasts, and viruses. In some cases, mice that
lack CD1d or NKT cells are more susceptible to certain
pathogens; in others, NKT cell activation by aGalCer amelio-
rates the disease. One clear principle is that aGalCer
modulation of host resistance to microbial pathogens requires
that it be administered early during the course of infection.
The greatest impact of NKT cells on infection is during the
initiation of the immune response. NKT cells are likely to be
functioning either as direct effector cells that transiently lower
the microbial burden in the host, leading to long-term
benefits, or as regulatory cells that modulate the immune
response (Skold and Behar, 2003). These interpretations are
consistent with the data from the M. tuberculosis model
showing that aGalCer treatment has no effect during
established infection and that repeated administration of
aGalCer provides no additional benefit compared to a single
dose (Chen et al., 1997).
NKT cells may exert their antimicrobial effect in three
ways: they may act (i) as direct effector cells, (ii) by
modulating adaptive immunity, or (iii) by modulating innate
immunity (Skold and Behar, 2003). Regarding the direct-
recognition pathway, bacterial glycolipid antigens are
recognized by the invariant TCR, including glycosphingoli-
pids found in Sphingomonas spp., and glycerol-based
antigens that have a wider distribution.
It is certain, however, that some bacteria, such as
Salmonella spp. and E. coli, do not have glycolipids for the
invariant TCR. It therefore remains to be determined which
types of microorganism have such antigens, and if this is
confined predominantly to certain types; for example,
extracellular bacteria, those that are not Gram-positive or
those lacking LPS (Tupin et al., 2007).
On the other hand, it is also clear that, in certain models,
the influence of NKT cells on the innate immune system plays
an important role in host defense. For example, NKT cells
appear to enhance the recruitment of granulocytes to the lung
following infection with P. aeruginosa (Nieuwenhuis et al.,
2002). Following infection with viruses, NKT cell-mediated
activation of NK cells contributes to host resistance in CMV
infection (van Dommelen et al., 2003). Finally, there is
evidence from several models that NKT cells can modulate
the adaptive immune response. This was observed as an
alteration of the Th1/Th2 polarization in malaria (Gonzalez-
Aseguinolaza et al., 2002; Hansen et al., 2003) or
B. burgdorferi-caused disease (Kumar et al., 2000) or a change
in T-cell responsiveness after an infection with C. neoformans
(Kawakami et al., 2001) and RSV (Johnson et al., 2002).
Cancer immunity
Many reports support the hypothesis that treatment with
aGalCer is beneficial to the prevention of the growth and
metastasis of certain tumors in mice (Smyth et al., 2002a, b).
This effect occurs at least in part through NK-like direct
cytotoxic action of NKT cells on tumor cells, because
Va14Vb8 transgenic mice but not NKT cell-deficient mice
were protected against experimental liver metastasis of
melanoma upon stimulation with aGalCer in vivo (Kawano
et al., 1997). However, NK and CD8þ T-cells also
contribute to the cytotoxic effector mechanisms as a
secondary effect of IFNg produced by activated NKT cells
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(Nakagawa et al., 2001; Smyth et al., 2002a, b). aGalCer
presented by mouse or human CD1d strongly stimulates
mouse or human NKT cells and mediates their direct or
indirect antitumor responses. The aGalCer/CD1d complex
activates NKT cells mediating perforin-dependent direct
cytotoxicity and also upregulating CD40L on NKT cells,
leading to the activation of DC to produce IL-12 (Kitamura
et al., 1999; Tomura et al., 1999; Seino et al., 2006). IL-12
from DC activates NKT cells to produce IFNg which in turn
stimulates NK cells and CD8 CTLs mediating antitumor
cytotoxicity (Hayakawa et al., 2001; Smyth et al., 2002a, b)
as in the case of microbial infection (Brigl et al., 2003). IFNg
secreted by NKT and NK cells is required for the NKT cell-
mediated antitumor responses, as IFNg-deficient mice could
not induce antitumor responses (Smyth et al., 2002a, b).
This networking between NKT and NK cells may be an
important factor in the contribution of each of these
populations to natural anti-tumor immunity. IL-12 may also
be a critical component of NKT cell activation in natural anti-
tumor immunity (Smyth et al., 2000b). In tumor models
(B16F10 and RM-1) in which both NK and NKT cells clearly
contributed to tumor immunity, NKT cells were principally
required for the low-dose activities of IL-12. It is not
surprising that NKT cells are more sensitive to low doses of
IL-12 in vivo, given that NKT cells express higher levels of IL-
12R than NK cells (Kawamura et al., 1998).
Regarding the molecular mechanism for the killing of
tumor cells, it has been reported that IFN-g-mediated TRAIL
induction on NK cells plays a critical role in the antimeta-
static effects of IL-12 and aGalCer (Smyth et al., 2001a, b).
It has been further indicated that perforin-mediated killing by
NKT cells is also involved in the cytotoxicity against tumor
cells (Kawano et al., 1998). It has also been demonstrated
that, in the absence of aGalCer, NKT cells contribute to the
elimination of cancer cells or inhibiting the expansion of
cancer cell growth. In fact, experiments using Ja281-deficient
mice indicated a critical role for NKT cells in protection from
spontaneous tumors initiated by a chemical carcinogen, MCA
(Smyth et al., 2000a, b). Further evaluation of several MCA-
induced tumors, in conjunction with NKT cell-transfer
experiments, revealed that, in addition to NK cells, CD8þ
T-cells, perforin, IFN-g, and CD1d expression on antigen-
presenting cells, NKT cells play an important role in
protection against tumor growth (Smyth et al., 2001a, b).
Recent studies have revealed an involvement of
naturally occurring CD25þCD4þ FoxP3þ regulatory T-cells
suppressing NKT cell-mediated anti-tumor activity (prolifera-
tion, cytokine production, and cytotoxic activity) (Azuma et al.,
2003). In addition to CD25þCD4þ regulatory T-cells
mentioned above, certain types of NKT cells also act as
regulatory cells that suppress CD8 CTL-mediated anti-tumor
responses, although type I NKT cells are not involved in this
regulatory cascade (Seino et al., 2005). It has been shown that
the number of NKT cells is markedly decreased in peripheral
blood from advanced cancer patients (for example, in lung
cancer patients). In prostate cancer patients, the ex vivo
expansion of aGalCer-activated NKT cells and the amount of
IFNg produced by these cells is decreased (Tahir et al., 2001).
Similarly, NKT cells from different types of solid cancer patients
fail to proliferate even with aGalCer stimulation and produce
lower amounts of cytokines than those from healthy individuals
(Yanagisawa et al., 2002). These studies indicate that NKT cells
in cancer patients have some numerical and functional defects.
In addition to studies in cancer patients with solid tumors, Fujii
et al. (2003) have shown that patients with myelodysplastic
syndromes have a severe functional deficiency in NKT cells,
but not NK cells or CD4þ or CD8þ T cells.
ROLE IN SKIN DISEASES
NKT cells have been reported to play an active role in skin
diseases such as contact sensitivity, have been implicated in
atopic dermatitis, ultraviolet (UV)-induced immunosuppres-
sion, and are present in psoriasis skin lesions (see Table 4).
Contact sensitivity
Delayed-type hypersensitivity in the form of contact hyper-
sensitivity (CHS) to haptens is a clinically important
syndrome known as allergic contact dermatitis (ACD)
(Belsito, 1999). ACD is an important dermatologic disease
with considerable morbidity and economic impact; CD from
both irritant and allergic sources comprise 6–10% of all
dermatology clinic visits (Thyssen et al., 2007). Some studies
have focused on the role of NKT cells in CHS in experimental
mouse models (Askenase, 2001; Campos et al., 2003; Stein-
Streilein, 2003; Nieuwenhuis et al., 2005).
Campos et al. (2003) indicated a role for this cell type in
the early molecular events of CHS, in which NKT cells
respond to hapten application and interact with B-1
lymphocytes, resulting in production of hapten-specific
IgM. These findings were confirmed by an in vitro system
too (Campos et al., 2006). Askenase et al. (2004) assessed that
elicitation of CHS begins with an initiation process that
Table 4. NKT cells in skin diseases
Diseases Comments
Allergic contact dermatitis (a) Critical role in afferent phase of CHS in mouse models; (b) infiltration into CHS skin challenge sites in humans
Atopic dermatitis Inconsistent results (m circulating NKT cells in some studies and k circulating NKT in others)
Psoriasis (a) Increased infiltration into skin lesion; (b) pathogenic role in SCID mouse model
UV immunosuppression Responsible for the transfer of suppression from UV-irradiated mice to non-irradiated control (mice)
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results in T-cell recruitment. In fact, there are two starting
points, both involving cells of the innate immune system. The
first of these is an early phase of the initiation process. The
other is an actual initiation of the late elicited effector phase
due to recruitment of the T-cells. During the initiation phase,
which subsequently elicits T-cell recruitment, there is a
postulated release of endogenous glycolipids from the
sensitizing site, occurring within minutes of sensitization.
These glycolipids bind to CD1d on APCs, leading to the
activation of NKT cells; these release IL-4 to coactivate B-1
cells. In the second of the two mentioned starting points,
initiation of the effector phase occurs within minutes of
secondary local Ag challenge, when B-1 cell-derived IgM
antibodies trigger an elicitation cascade of innate responses.
This starts with a classical complement activation, generating
C5a, which in turn activates mast cells and platelets to release
TNFa and serotonin; these then activate endothelial cells,
leading to local T-cell recruitment. Another animal model
study confirmed the role of NKT cells in murine CHS with
impaired contact sensitization in Va14 gene-targeted mice
and examined the therapeutic role of antagonistic lipids that
bound to CD1d but do not activate NKT cells (Nieuwenhuis
et al., 2005). Such antagonistic lipids, when administered
topically to mouse skin or when administered systemically,
interfered with both the afferent and the efferent phases of
CHS (Nieuwenhuis et al., 2005), suggesting that the inhibi-
tion of CD1d antigen-presenting pathway to NKT cells
interfered with both phases of CHS.
Gober et al. (2008) reported that CD1d gene expression
was increased in elicitation sites of ACD relative to normal
human skin. Similarly, both CD161 gene expression and
variable region of TCR Va24, JaQ region of TCR gene
expression in skin lesions of ACD were increased relative to
normal skin, indicating that invariant NKT cells are com-
monly present in the T-lymphocyte infiltrate of ACD. It was
demonstrated that human invariant NKT cells regularly
appear in the lymphocytic infiltrate that occurs during the
elicitation phase of human ACD, either at the 48 or 96 hours
time frame of clinical readings of this skin reaction by
immunohistochemistry, real-time PCR, as well as nested
PCR. Lee et al. (2002a, b) reported that in healthy adults,
NKT cells are present at a very low frequency in the
peripheral blood, approximately 0.1% of the total population
of peripheral blood leukocytes. Based on this they
demonstrated the frequency of NKT cells in the ACD lesions
to range from 1.72 to as high as 33% of the total CD2þ
infiltrating T lymphocytes, this representing a relative
enrichment of NKT cells ranging from a 17- to 330-fold
enrichment above the normally very low frequency found in
the peripheral blood. This suggests that NKT cells may be
specifically recruited into ACD sites, rather than a passive
extravasation event, in which relative enrichment of
frequency relative to other cell types would be expected
not to occur.
The relationship between NKT cells and ACD is far to be
elucidated, even because there are some controversies.
Elkhal et al. (2006) reported that CD1d–/– mice were
able to mount an intact systemic immune response to
epicutaneous sensitization with the antigen in a murine
model of AD; although they also reported that NKT cells were
crucial for the development of AHR in this model. However,
it is important to notice that these experiments were
performed in a murine model of AD and the sensitization
was executed with OVA, so that a protein contact dermatitis
was reproduced.
The importance of NKT cells, at least, in the priming phase
of CS is reinforced by numerous experiments, even if further
work is needed to be performed to better understand the role
of NKT cells in the elicitation phase too, and in ACD in
general.
Atopic dermatitis
The relationship between AD and NKT cells has not been
well investigated as in ACD; furthermore contradictory results
are reported. Takahashi et al. (2003) reported that the
proportion of Va24þ NKT cells in the peripheral blood of
AD patients was markedly decreased, and only CD4 subset
of Va24þ NKT cells was significantly diminished.
Oishi et al. (2000) reported that in atopic disease (three
AD patients and six asthma patients), the number of DN
Va24þ NKT cells but not that of CD4þ Va24þ NKT cells
was decreased. Ilhan et al. showed that percentages of
Va24þCD161þ NKT cell subtypes were significantly lower
in patients with atopic dermatitis than healthy individuals,
suggesting that these cell subtypes may be involved in the
immunopathogenesis of atopic dermatitis (Ilhan et al., 2007).
On the other hand, Magnan et al. (2000) reported that the
number of NKT cells, defined by the expression of
CD4þVa24þ was increased in AD patients. Prell et al.
(2003) analysis of Va24þCD161þ NKT cell frequencies at
both cellular and molecular levels failed to reveal significant
differences in peripheral blood of atopic and non-atopic
probands. More studies are needed to establish the impor-
tance of NKT cells in AD.
Psoriasis
There is considerable interest in NKT cells and their role in
the pathophysiology of psoriasis. Increased NKT cells were
consistently observed in psoriasis lesions by different groups
(Bonish et al., 2000; Cameron et al., 2002; Vissers et al.,
2004; Liao et al., 2006; Ottaviani et al., 2006), although the
exact role played by these cells is yet to be defined precisely.
Nickoloff et al. (2000)(Bonish et al., 2000) demonstrated that
psoriatic KCs overexpressed CD1d and NKT cells, which can
be activated to elaborate IFNg when cultured with CD1d
overexpressing KCs. These results provided a pathogenetic
link between psoriatic KCs, which overexpress CD1d and
NKT cells infiltrating the lesions. Experiments in severe
combined immunodeficient mice have also shown that
injection of human cells of NKT characteristics into
transplanted psoriatic skin could drive lesion development
(Nickoloff et al., 2000). Zhao et al. (2008) showed increased
densities of NKT cells using a set of precise markers for
classical NKT cells, anti-Va24, and anti-Vb11 mAbs, in
psoriatic lesions, especially in the epidermis, compared with
healthy adult skin. These data were confirmed by real-time
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PCR too. Also CD1d expression was more extensive in
psoriasis than in normal skin. They also reported that PKCz,
an important enzyme for CD1d expression in KCs, was
overexpressed in psoriatic lesions.
Skin cancer
Ultraviolet radiation is carcinogenic and immunosuppressive.
UV-induced immune suppression is mediated by antigen-
specific T-cells, which can transfer suppression to normal
recipients. These cells are essential for controlling skin cancer
development in the UV-irradiated host and in suppressing
other immune responses, such as DTH. The development of
UV-induced skin cancers in the primary UV-irradiated host
and the ability to transfer immune suppression from UV-
irradiated animals to normal recipients is controlled by
CD4þ T cells (Fisher and Kripke, 1982; Ullrich and Kripke,
1984). Despite having been identified many years ago
(Daynes and Spellman, 1977; Fisher and Kripke, 1977), the
exact identity of the cells that transfer suppression of tumor
immunity remains unknown. The immunosuppressive me-
chanism is also unclear, but IL-4 secretion is involved (Rivas
and Ullrich, 1994). Two types of CD4þ T cells secrete IL-4:
Th2 and NKT cells. Moodycliffe et al. (2000) demonstrated a
critical role for NKT cells in mediating UV-induced immune
suppression and in the regulation of sunlight-induced skin
carcinogenesis. They showed that there was no immune
suppression in UV-irradiated CD1d-deficient mice. They
explained that although their data showed that UV-induced
NKT cells mediate antigen-specific immune suppression, they
were not able to definitively identify the ultimate suppressor
cell. It was hypothesized that UV-induced IL-4–secreting NKT
cells directly suppress effector cell function. Alternatively,
UV-induced NKT cells may initiate a cascade of events in
which recipient T-cells are activated to secrete IL-4 and
suppress DTH and tumor immunity (Singh et al., 1999).
CONCLUSIONS
NKT cells have been assessed to represent the ‘‘trait d’union’’
between innate and adaptive immunity. They are involved in
autoimmunity, infections, tumor surveillance, and allergy.
They play an active role in skin diseases such as contact
sensitivity, have been implicated in atopic dermatitis, UV-
induced immunosuppression, and are present in psoriasis
skin lesions. Thus, NKT-cells are emerging as an important
subset of lymphocytes, with a protective role in host defense
and a pathogenic role in certain immune-mediated disease
states.
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